Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Strong Trading Volume – Should You Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares saw an uptick in trading volume on Tuesday . 81,708 shares traded hands during mid-day trading, a decline of 17% from the previous session’s volume of 98,114 shares.The stock last traded at $10.48 and had previously closed at $10.62.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The stock has a market cap of $17.69 billion, a P/E ratio of 13.68, a PEG ratio of 0.81 and a beta of 0.19. The company has a 50 day simple moving average of $11.06 and a 200 day simple moving average of $9.57. The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Friday, January 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.19 by $0.09. The firm had revenue of $966.53 million for the quarter, compared to analysts’ expectations of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.70% and a net margin of 41.82%. Sell-side analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.